For over 50 years, pharmaceutical companies have looked to 3M Drug Delivery Systems for ingenious inhalation and transdermal systems, components and manufacturing to help enable success.
For over 50 years, pharmaceutical companies have looked to 3M Drug Delivery Systems for ingenious inhalation and transdermal systems, components and manufacturing to help enable success. With proven international accomplishments in technology, development, manufacturing and regulatory, partnering with 3M helps ensure a smooth process critical to speed to market.
Systems: 3M can fulfill your inhalation needs with both Metered Dose Inhaler and Dry Powder Inhaler systems. Our transdermal offerings include microneedle and passive drug-in-adhesive technologies.
Components: 3M offers a wide variety of transdermal backings, membranes, liners and tapes, as well as the FDA-approved 3M Integrated Dose by Dose Counter, in conjunction with an MDI product and the most complete line of compatible inhalation valves, canisters and actuators.
Contract Manufacturing: Our cGMP compliant facilities can reliably meet your inhalation, transdermal, transmucosal, oral or topical needs from clinical to commercial supply.
We understand partners may be looking for ways to improve drug performance and patient compliance. As we develop new products with our partners, we leverage company-wide resources and more than 100 years of time-tested 3M technologies, including films, adhesives, hardware design, coatings and manufacturing. In addition, we can assess potential partners’ needs to determine whether our technology is a fit with a complimentary feasibility study.
Let us prove why 3M technology is relied upon by 50% of all MDIs worldwide and 80% of all transdermal systems in the U.S. Visit www.3m.com/dds to learn more.
Exosomes Field Advances with Milestones Achieved by EXO Biologics and ExoXpert
December 4th 2024EXO Biologics and ExoXpert, an EXO Biologics subsidiary, have received GMP certification of a European manufacturing facility for exosomes and have successfully loaded mRNA and DNA payloads into GMP-grade exosomes for drug delivery.
Why is the PDA Pharmaceutical Microbiology Conference the Hottest Ticket in the Industry?
October 10th 2024Get a glimpse of the power and popularity behind the PDA Pharmaceutical Microbiology Conference from two planning committee members, Julia Marre, PhD (Associate Director, Scientific and Regulatory Affairs at Pocket Naloxone Corp) and Dawn Watson (Executive Director, Global Micro Quality and Sterility Assurance at Merck). This candid conversation reveals why this industry event is so influential…and always sold out! The speakers discuss what makes the PDA Pharmaceutical Microbiology Conference so vital to industry professionals, as well as how to become a part of this dynamic professional community.